The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.
- First select the CSR Section, then a Table/Figure from that section.
- Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.
To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR(PDF, 524KB) and Technical Notes(PDF, 752KB) pages.
Download and Print: Download Printer-friendly PDF Download data
Table 35.2
Comparison of Period Survivala (Percent) using different Expected Survival Life Tables
By Primary Cancer Site, Race and Sex, 2014 Period Survival Estimate
| Site | Male | Female | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All Races | White | Black | All Races | White | Black | |||||||
| USLTb | SESc | USLTb | SESc | USLTb | SESc | USLTb | SESc | USLTb | SESc | USLTb | SESc | |
| All Sites | 65.7 | 65.7 | 65.7 | 65.7 | 63.1 | 63.0 | 68.0 | 67.9 | 68.6 | 68.5 | 59.7 | 59.7 |
| Oral Cavity & Pharynx | 64.4 | 64.4 | 66.0 | 66.0 | 47.2 | 47.2 | 67.6 | 67.6 | 68.3 | 68.2 | 54.4 | 54.4 |
| Esophagus | 19.9 | 19.9 | 20.8 | 20.8 | 12.0 | 12.0 | 23.0 | 22.9 | 24.0 | 23.9 | 16.1 | 16.1 |
| Stomach | 28.9 | 28.8 | 27.8 | 27.6 | 26.1 | 26.0 | 36.8 | 36.6 | 36.2 | 35.9 | 40.0 | 39.9 |
| Colon & Rectum | 63.5 | 63.5 | 64.0 | 64.0 | 55.8 | 55.7 | 64.9 | 64.8 | 65.4 | 65.2 | 60.0 | 60.0 |
| Liver & Intrahepatic Bile Duct | 17.6 | 17.6 | 17.1 | 17.0 | 14.0 | 14.0 | 18.8 | 18.7 | 17.9 | 17.8 | 16.5 | 16.6 |
| Pancreas | 9.5 | 9.5 | 9.4 | 9.4 | 8.4 | 8.4 | 9.4 | 9.3 | 9.0 | 9.0 | 10.9 | 10.9 |
| Larynx | 60.4 | 60.5 | 61.8 | 61.9 | 50.7 | 50.8 | 59.8 | 60.0 | 61.2 | 61.3 | 51.8 | 51.9 |
| Lung & Bronchus | 15.6 | 15.7 | 15.7 | 15.8 | 13.3 | 13.3 | 22.7 | 22.7 | 22.7 | 22.7 | 20.3 | 20.3 |
| Melanoma of the Skin | 90.0 | 89.9 | 89.1 | 89.0 | 57.1 | 56.9 | 94.5 | 94.4 | 94.1 | 94.0 | 67.5 | 67.5 |
| Breast | - | - | - | - | - | - | 89.9 | 89.9 | 90.8 | 90.7 | 81.6 | 81.6 |
| Cervix | - | - | - | - | - | - | 54.7 | 54.5 | 55.6 | 55.4 | 44.7 | 44.7 |
| Corpus & Uterus, NOS | - | - | - | - | - | - | 80.0 | 79.9 | 82.5 | 82.4 | 59.3 | 59.4 |
| Ovary | - | - | - | - | - | - | 31.5 | 31.5 | 32.1 | 32.1 | 21.3 | 21.3 |
| Prostate | 98.7 | 98.4 | 98.9 | 98.5 | 97.5 | 97.4 | - | - | - | - | - | - |
| Urinary Bladder | 77.8 | 77.9 | 78.1 | 78.1 | 66.0 | 65.5 | 72.4 | 72.3 | 73.4 | 73.3 | 55.5 | 55.4 |
| Kidney & Renal Pelvis | 74.1 | 74.1 | 73.9 | 73.9 | 75.3 | 75.3 | 76.4 | 76.4 | 76.3 | 76.3 | 78.0 | 78.2 |
| Hodgkin Lymphoma | 85.9 | 85.8 | 86.3 | 86.2 | 81.1 | 81.2 | 87.9 | 87.8 | 87.9 | 87.7 | 87.5 | 87.5 |
| Non-Hodgkin Lymphoma | 70.1 | 70.0 | 70.3 | 70.2 | 65.1 | 65.0 | 73.9 | 73.7 | 74.1 | 74.0 | 71.4 | 71.4 |
| Myeloma | 51.3 | 51.2 | 50.7 | 50.6 | 52.2 | 52.0 | 52.2 | 52.1 | 51.2 | 51.0 | 52.9 | 52.9 |
| Leukemia | 63.3 | 63.3 | 63.3 | 63.3 | 58.2 | 58.1 | 60.0 | 60.0 | 60.7 | 60.7 | 52.1 | 52.0 |
| Acute Lymphocytic Leukemia | 68.9 | 68.9 | 68.5 | 68.5 | 64.3 | 64.3 | 68.5 | 68.5 | 69.0 | 68.9 | 59.9 | 60.0 |
Footnotes:
a SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Period survival provides a 2014 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2012-2014: 0-1 year survival), (2011-2013: 1-2 year survival), (2010-2012: 2-3 year survival), (2009-2011: 3-4 year survival), (2008-2010: 4-5 years survival). Based on follow-up of patients into 2015.
b Expected survival rates are derived from the U.S. Annual Life Tables.
c Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.
For more information on the life tables, see: https://seer.cancer.gov/expsurvival/ .
Page Navigation: << Previous Next >>
The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.